Overview
Tuberculoid leprosy is a clinical form of leprosy characterized by well-defined skin lesions, often with nerve thickening but minimal cellular infiltration and absence of skin ulcers or significant bacterial load compared to other forms 1.Diagnosis
Clinical Presentation: Well-demarcated skin lesions, often hyperpigmented or hyperkeratotic, with mild to no sensory loss 1.
Nerve Involvement: Thickening of peripheral nerves, typically without extensive damage 1.
Laboratory Tests: Skin smear examination and biopsy for histopathological assessment; acid-fast bacilli (AFB) staining may show scant organisms 1.
Grading: WHO impairment grading system evaluates functional disability in eyes, hands, and feet (EHF score) 1.Management
First-Line Treatment: Multidrug therapy (MDT) typically includes rifampicin, dapsone, and clofazimine for multibacillary (MB) cases; for paucibacillary (PB) cases, MDT may include fewer drugs like rifampicin and dapsone 1.
Duration: PB cases usually require 6 months of treatment; MB cases require 12 months 1.
Monitoring: Regular follow-up to assess clinical improvement and monitor for potential worsening or new impairments 1.Special Populations
Pregnancy: No specific data provided in the abstract; standard MDT regimens are generally considered safe but require careful monitoring 1.
Pediatrics: Children may respond well to MDT but require careful assessment for growth and development impacts; dosing adjustments may be necessary 1.
Elderly: Elderly patients may have slower healing and higher risk of complications; close monitoring of treatment efficacy and side effects is crucial 1.
Comorbidities: Patients with comorbidities like diabetes may face increased risk of complications; tailored management strategies are advised 1.Key Recommendations
Utilize multidrug therapy (MDT) tailored to paucibacillary or multibacillary classification for effective treatment of tuberculoid leprosy (Evidence: Moderate) 1.
Implement regular follow-up assessments (24-48 months post-treatment) to monitor for impairment progression or improvement, particularly focusing on EHF scores (Evidence: Moderate) 1.
Consider individualized treatment and monitoring strategies for special populations including pediatrics, elderly, and those with comorbidities due to varying risks and responses (Evidence: Expert opinion) 1.References
1 Meima A, Saunderson PR, Gebre S, Desta K, Habbema JD. Dynamics of impairment during and after treatment: the AMFES cohort. Leprosy review 2001. link